Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yakir Rottenberg

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Lung Cancer (Amsterdam, Netherlands)|March 10, 2023
Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancerSameh Daher, Alona Zer, Roi Tschernichovsky, et al.
Medicine|May 18, 2017
Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patientsAviad Zick, Tamar Peretz, Michal Lotem, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)Jair Bar, Nir Peled, Shiruyeh Schokrpur, et al.
Frontiers in Medicine|October 16, 2023
A clinical evaluation of an <i>ex vivo</i> organ culture system to predict patient response to cancer therapyShay Golan, Vered Bar, Seth J Salpeter, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Lung Cancer (Amsterdam, Netherlands)|March 10, 2023
Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancerSameh Daher, Alona Zer, Roi Tschernichovsky, et al.
Medicine|May 18, 2017
Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patientsAviad Zick, Tamar Peretz, Michal Lotem, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)Jair Bar, Nir Peled, Shiruyeh Schokrpur, et al.
Frontiers in Medicine|October 16, 2023
A clinical evaluation of an <i>ex vivo</i> organ culture system to predict patient response to cancer therapyShay Golan, Vered Bar, Seth J Salpeter, et al.
Pageof 7